209984-57-6 | Ly411575

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$41.00	$29.00
5mg	98%	in stock	$118.00	$83.00
10mg	98%	in stock	$203.00	$142.00
25mg	98%	in stock	$345.00	$241.00
100mg	98% by HPLC	in stock	$1,192.00	$835.00
500mg	98% by HPLC	in stock	$3,722.00	$2,605.00
1000mg	98% by HPLC	in stock	$5,922.00	$4,145.00

Description

• Catalog Number: AB19687
• Chemical Name: Ly411575
• CAS Number: 209984-57-6
• Molecular Formula: C26H23F2N3O4
• Molecular Weight: 479.4753
• MDL Number: MFCD09832551
• SMILES: Fc1cc(F)cc(c1)[C@@H](C(=O)N[C@H](C(=O)N[C@H]1c2ccccc2c2c(N(C1=O)C)cccc2)C)O

Computed Properties

• Complexity: 789
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 3
• Heavy Atom Count: 35
• Hydrogen Bond Acceptor Count: 6
• Hydrogen Bond Donor Count: 3
• Rotatable Bond Count: 5
• XLogP3: 3

Literature

• A phase 3 trial of semagacestat for treatment of Alzheimer's disease.

  The New England journal of medicine 20130725

• Targeting the ERAD pathway via inhibition of signal peptide peptidase for antiparasitic therapeutic design.

  Proceedings of the National Academy of Sciences of the United States of America 20121226

• The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole.

  Drug metabolism and disposition: the biological fate of chemicals 20121001

• Semagacestat pharmacokinetics are not significantly affected by formulation, food, or time of dosing in healthy participants.

  Journal of clinical pharmacology 20120601

• miR-9 controls the timing of neurogenesis through the direct inhibition of antagonistic factors.

  Developmental cell 20120515

• A brain aggregate model gives new insights into the pathobiology and treatment of prion diseases.

  Journal of neuropathology and experimental neurology 20120501

• First and second generation γ-secretase modulators (GSMs) modulate amyloid-β (Aβ) peptide production through different mechanisms.

  The Journal of biological chemistry 20120406

• Γ-secretase modulators do not induce Aβ-rebound and accumulation of β-C-terminal fragment.

  Journal of neurochemistry 20120401

• QT effect of semagacestat at therapeutic and supratherapeutic doses.

  International journal of clinical pharmacology and therapeutics 20120401

• Differential effects between γ-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20120208

• A canine model to evaluate efficacy and safety of γ-secretase inhibitors and modulators.

  Journal of Alzheimer's disease : JAD 20120101

• Evaluation of the performance of novel Aβ isoforms as theragnostic markers in Alzheimer's disease: from the cell to the patient.

  Neuro-degenerative diseases 20120101

• Translatability scoring in drug development: eight case studies.

  Journal of translational medicine 20120101

• Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease.

  Expert opinion on drug discovery 20120101

• Modulation of γ-secretase activity by multiple enzyme-substrate interactions: implications in pathogenesis of Alzheimer's disease.

  PloS one 20120101

• Amyloid-β(1-15/16) as a marker for γ-secretase inhibition in Alzheimer's disease.

  Journal of Alzheimer's disease : JAD 20120101

• γ-Secretase modulator in Alzheimer's disease: shifting the end.

  Journal of Alzheimer's disease : JAD 20120101

• pPKCα-mediated effect on in vitro Aβ production in response to gamma secretase inhibitor LY411575 in rat CTXTNA2 astrocytes.

  Journal of biological regulators and homeostatic agents 20120101

• Quantitative pharmacokinetic/pharmacodynamic analyses suggest that the 129/SVE mouse is a suitable preclinical pharmacology model for identifying small-molecule γ-secretase inhibitors.

  The Journal of pharmacology and experimental therapeutics 20111201

• [Gamma-secretase inhibitors and modulators].

  Nihon rinsho. Japanese journal of clinical medicine 20111201

• Drugs: a tangled web of targets.

  Nature 20110713

• Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab.

  Alzheimer's & dementia : the journal of the Alzheimer's Association 20110701

• What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us.

  Annals of neurology 20110201

• New pathway links γ-secretase to inflammation and memory while sparing notch.

  Annals of neurology 20110101

• Validation of ELISA methods for quantification of total tau and phosporylated-tau181 in human cerebrospinal fluid with measurement in specimens from two Alzheimer's disease studies.

  Journal of Alzheimer's disease : JAD 20110101

• BACE-1 inhibition prevents the γ-secretase inhibitor evoked Aβ rise in human neuroblastoma SH-SY5Y cells.

  Journal of biomedical science 20110101

• Interacting with γ-secretase for treating Alzheimer's disease: from inhibition to modulation.

  Current medicinal chemistry 20110101

• Genetics. Gamma-secretase and human disease.

  Science (New York, N.Y.) 20101119

• What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer's disease?

  Biological psychiatry 20101115

• Alzheimer's failure raises questions about disease-modifying strategies.

  Nature reviews. Drug discovery 20101001

• NerveCenter: Phase III Alzheimer trial halted: Search for therapeutic biomarkers continues.

  Annals of neurology 20101001

• ACS chemical neuroscience molecule spotlight on semagacestat (LY450139).

  ACS chemical neuroscience 20100818

• [Progress in the development of anti-amyloid drugs for treatment of Alzheimer's disease.].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20100701

• Disposition and metabolism of semagacestat, a {gamma}-secretase inhibitor, in humans.

  Drug metabolism and disposition: the biological fate of chemicals 20100401

• In response to 'a gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system'.

  Annals of neurology 20100101

• Acute effect on the Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogs.

  Journal of Alzheimer's disease : JAD 20100101

• Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease.

  Alzheimer's research & therapy 20100101

• Amyloid precursor protein selective gamma-secretase inhibitors for treatment of Alzheimer's disease.

  Alzheimer's research & therapy 20100101

• Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease.

  Journal of medicinal chemistry 20091022

• Differential effects of gamma-secretase and BACE1 inhibition on brain Abeta levels in vitro and in vivo.

  Journal of neurochemistry 20090901

• A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system.

  Annals of neurology 20090701

• Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease.

  Expert opinion on pharmacotherapy 20090701

• Semagacestat, a gamma-secretase inhibitor for the potential treatment of Alzheimer's disease.

  Current opinion in investigational drugs (London, England : 2000) 20090701

• gamma-Secretase inhibitor reduces diet-induced atherosclerosis in apolipoprotein E-deficient mice.

  Biochemical and biophysical research communications 20090529

• Committed neuronal precursors confer astrocytic potential on residual neural precursor cells.

  Developmental cell 20090201

• Requirement of Notch activation during regeneration of the intestinal epithelia.

  American journal of physiology. Gastrointestinal and liver physiology 20090101

• A small molecule inhibitor of signal peptide peptidase inhibits Plasmodium development in the liver and decreases malaria severity.

  PloS one 20090101

• Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575.

  Molecular neurodegeneration 20090101

• Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition.

  The Journal of pharmacology and experimental therapeutics 20081101

• Notch1 and TGFbeta1 cooperatively regulate Foxp3 expression and the maintenance of peripheral regulatory T cells.

  Blood 20080901

• Molecule of the month. Semagacestat.

  Drug news & perspectives 20080901

• Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease.

  Archives of neurology 20080801

• A multigram chemical synthesis of the gamma-secretase inhibitor LY411575 and its diastereoisomers.

  Bioorganic & medicinal chemistry letters 20071115

• Epidermal growth factor receptor and notch pathways participate in the tumor suppressor function of gamma-secretase.

  The Journal of biological chemistry 20071102

• Novel orally active, dibenzazepinone-based gamma-secretase inhibitors.

  Bioorganic & medicinal chemistry letters 20071101

• Insensitivity to Abeta42-lowering nonsteroidal anti-inflammatory drugs and gamma-secretase inhibitors is common among aggressive presenilin-1 mutations.

  The Journal of biological chemistry 20070824

• Dominance of amyloid precursor protein sequence over host cell secretases in determining beta-amyloid profiles studies of interspecies variation and drug action by internally standardized immunoprecipitation/mass spectrometry.

  The Journal of pharmacology and experimental therapeutics 20070301

• Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase.

  Clinical neuropharmacology 20070101

• Studies to investigate the in vivo therapeutic window of the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY411,575) in the CRND8 mouse.

  The Journal of pharmacology and experimental therapeutics 20061201

• Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139.

  The Journal of pharmacology and experimental therapeutics 20061101

• [The molecular mechanism of Notch-induced transformation and the therapeutic potential of its inhibitor].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20060701

• Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease.

  Neurology 20060227

• Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide].

  The Journal of pharmacology and experimental therapeutics 20050501

• Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers.

  Clinical neuropharmacology 20050101

• Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY-411575).

  The Journal of pharmacology and experimental therapeutics 20040401